Improvement in symptoms after H_2-receptor antagonist-based therapy for eradication of H pylori infection  

作　　者：Takeshi Hagiwara Mototsugu Kato Tomonori Anbo Akimichi Imamura Toshihiro Suga Takumi Uchida Akira Fujinaga Manabu Nakagawa Soichi Nakagawa Yuichi Shimizu Jyunji Yamamoto Hiroshi Takeda Masahiro Asaka 

机构地区：[1]Department of Gastroenterology,Sapporo-Kosei General Hospital,Sapporo,Hokkaido 060-4876,Japan [2]Division of Endoscopy,Hokkaido University Hospital,Sapporo,Hokkaido 060-4876,Japan [3]Department of Internal Medicine,Abashiri-Kosei General Hospital,Abashiri,Japan [4]Department of Gastroenterology,Graduate School of Medicine Hokkaido University,Sapporo,Hokkaido 060-4876,Japan

出　　处：《World Journal of Gastroenterology》2007年第28期3836-3840,共5页世界胃肠病学杂志（英文版）

摘　　要：AIM: To investigate the therapeutic effects of triple therapy combining lafutidine with clarithromycin and amoxicillin on H pylori infection and the resolution of gastroesophageal symptoms after eradication. METHODS: We conducted a randomized, multicenter, open-label controlled trial to compare the effective-ness of a triple therapy of lafutidine, clarithromycin, and amoxicillin (lafutidine group) with that of a triple therapy of lansoprazole, clarithromycin, and amoxicillin (lansopra- zole group) in patients with H pylori infection. The study group comprised 22 patients with gastric ulcers and 18 patients with duodenal ulcers who had H pylori infection. RESULTS: H pylori eradication rates were similar in the lafutidine group (14/20, 70%) and the lansoprazole group (14/20, 70%). Gastroesophageal reflux and ab-dominal symptoms improved after eradication therapy in both groups, whereas abdominal discomfort, diarrhea, and constipation were unchanged. H pylori status had no apparent effect on improvement of gastroesophageal reflux or abdominal symptoms after treatment. Adverse events were similar in both groups. CONCLUSION: The triple therapy including lafutidine is equivalent to triple therapy including lansoprazole in terms of H pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms.These results are attributed to the fact that lafutidine has strong, continuous antisecretory activity, unaffected by CYP2C19 polymorphisms.AIM： To investigate the therapeutic effects of triple therapy combining lafutidine with clarithromycin and amoxicillin on H pylori infection and the resolution of gastroesophageal symptoms after eradication.METHODS： We conducted a randomized, multicenter, open-label controlled trial to compare the effectiveness of a triple therapy of lafutidine, clarithromycin, and amoxicillin （lafutidine group） with that of a triple therapy of lansoprazole, clarithromycin, and amoxicillin （lansoprazole group） in patients with Hpylori infection. The study group comprised 22 patients with gastric ulcers and 18 patients with duodenal ulcers who had Hpylori infection.RESULTS： H pylori eradication rates were similar in the lafutidine group （14/20, 70%） and the lansoprazole group （14/20, 70%）. Gastroesophageal reflux and ab- dominal symptoms improved after eradication therapy in both groups, whereas abdominal discomfort, diarrhea, and constipation were unchanged. H pylori status had no apparent effect on improvement of gastroesophageal reflux or abdominal symptoms after treatment. Adverse events were similar in both groups.CONCLUSION： The triple therapy including lafutidine is equivalent to triple therapy including lansoprazole in terms of H pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms.These results are attributed to the fact that lafutidine has strong, continuous antisecretory activity, unaffected by CYP2C19 polymorphisms.

关 键 词：HPYLORI Gastroesophageal symptoms LAFUTIDINE LANSOPRAZOLE 

分 类 号：R573.1[医药卫生—消化系统]